Macrogenics Inc
NASDAQ:MGNX 3:11:23 PM EDT
| Market Cap (Intraday) | 228.32M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.47 |
| 50-Day MA | $4.05 |
| 200-Day MA | $9.82 |
Macrogenics Inc Stock, NASDAQ:MGNX
9704 Medical Center Drive, Rockville, Maryland 20850-3368
United States of America
Phone: +1.301.251.5172
Number of Employees: 339
Description
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.